Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
36.30 K
Value Traded
222.89
Short % Float
-
Days to Cover
1.0
+6.9%Week
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
821.69 K
EPS (TTM)
-0.12
P/E Ratio
-
Ent. Value
1.51 M
Total Shares
132.53 M
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
EVFM Catalyst Timeline
Dated clinical, regulatory and corporate events for Evofem Biosciences, Inc.
Past FDA Catalysts and PDUFA Decisions
How EVFM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2022-01-26 | Solosec (secnidazole) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every EVFM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Zhang YanOfficer (CFO) | Sell | -104 | $0.04 | 01/12/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in EVFM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 0 % | 2.92 M | 2.58 M |
Ownership Trends
EVFM Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
11.4K
Shares Sold Short
+134.6% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
109.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EVFM ranks across every disease it competes in
Competitive Position is a premium feature
See how EVFM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEVFM News
About Evofem Biosciences, Inc.
BIOPHARMAWATCH ELITE
Trade the next EVFM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime